Clinical trial · Observational
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia
C-X-C Chemokine Receptor 4 as Prognostic Marker in Chronic Lymphocytic Leukemia
NCT03150849CI-TRIAL-00027537unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chronic lymphocytic leukemia is the most common type of chronic leukemia, accounting for approximately 40% of all leukemias and mainly affecting older individuals. As it has a highly variable clinical course, identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with chronic lymphocytic leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| C-X-C Chemokine Receptor 4 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- patient group
- description
- patient with chronic lymphocytic leukemia
- interventionNames
- Diagnostic Test: C-X-C Chemokine Receptor 4
- label
- control group
- description
- healthy control group
- interventionNames
- Diagnostic Test: C-X-C Chemokine Receptor 4
Primary outcomes (1)
- measure
- The level of C-X-C Chemokine Receptor 4 in chronic lymphocytic leukemia patient and healthy individual
- timeFrame
- 2 years
- description
- the level of C-X-C Chemokine Receptor 4 marker assessed by flowcytometry in a blood sample
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * All patients are newly diagnosed as chronic lymphocytic leukemia Exclusion Criteria: * Patients with associated malignancies. * Chronic lymphocytic leukemia patients on chemotherapy
References
Publications (7)
- BACKGROUNDPalmesino E, Moepps B, Gierschik P, Thelen M. Differences in CXCR4-mediated signaling in B cells. Immunobiology. 2006;211(5):377-89. doi: 10.1016/j.imbio.2005.12.003. Epub 2006 Apr 18. PMID 16716807
- BACKGROUNDBurger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009 Jan;23(1):43-52. doi: 10.1038/leu.2008.299. Epub 2008 Nov 6. PMID 18987663
- BACKGROUNDBarretina J, Junca J, Llano A, Gutierrez A, Flores A, Blanco J, Clotet B, Este JA. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol. 2003 Aug;82(8):500-505. doi: 10.1007/s00277-003-0679-0. Epub 2003 May 29. PMID 12783211
- BACKGROUNDMarchese A. Endocytic trafficking of chemokine receptors. Curr Opin Cell Biol. 2014 Apr;27:72-7. doi: 10.1016/j.ceb.2013.11.011. Epub 2013 Dec 14. PMID 24680433
- BACKGROUNDDomanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013 Jan;49(1):219-30. doi: 10.1016/j.ejca.2012.05.005. Epub 2012 Jun 9. PMID 22683307
- BACKGROUNDVlad A, Deglesne PA, Letestu R, Saint-Georges S, Chevallier N, Baran-Marszak F, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res. 2009 Aug 15;69(16):6387-95. doi: 10.1158/0008-5472.CAN-08-4750. Epub 2009 Aug 4. PMID 19654311
- BACKGROUNDLi SH, Dong WC, Fan L, Wang GS. Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811. Am J Transl Res. 2016 Sep 15;8(9):3812-3821. eCollection 2016. PMID 27725861